155 related articles for article (PubMed ID: 30912699)
1. Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis.
Berdeja JG; Heinrich MC; Dakhil SR; Goldberg SL; Wadleigh M; Kuriakose P; Cortes J; Radich J; Helton B; Rizzieri D; Paley C; Dautaj I; Mauro MJ
Leuk Lymphoma; 2019 Oct; 60(10):2384-2393. PubMed ID: 30912699
[TBL] [Abstract][Full Text] [Related]
2. Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akkaynak DZ; Dag IM; Ilhan O
Expert Opin Pharmacother; 2016 Oct; 17(14):1851-8. PubMed ID: 27501474
[TBL] [Abstract][Full Text] [Related]
3. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
4. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.
Giles FJ; Rea D; Rosti G; Cross NCP; Steegmann JL; Griskevicius L; le Coutre P; Coriu D; Petrov L; Ossenkoppele GJ; Mahon FX; Saussele S; Hellmann A; Koskenvesa P; Brümmendorf TH; Gastl G; Castagnetti F; Vincenzi B; Haenig J; Hochhaus A
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1585-1596. PubMed ID: 28364360
[TBL] [Abstract][Full Text] [Related]
5. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.
Hughes TP; Lipton JH; Spector N; Cervantes F; Pasquini R; Clementino NC; Dorlhiac Llacer PE; Schwarer AP; Mahon FX; Rea D; Branford S; Purkayastha D; Collins L; Szczudlo T; Leber B
Blood; 2014 Jul; 124(5):729-36. PubMed ID: 24948656
[TBL] [Abstract][Full Text] [Related]
6. Optimal Response in a Patient With CML Expressing
Manzella L; Tirrò E; Vitale SR; Puma A; Consoli ML; Tambè L; Pennisi MS; DI Gregorio S; Romano C; Tomarchio C; DI Raimondo F; Stagno F
In Vivo; 2020; 34(3):1481-1486. PubMed ID: 32354950
[TBL] [Abstract][Full Text] [Related]
7. Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up.
Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akin G; Dag IM; Ilhan O
Hematology; 2018 Dec; 23(10):771-777. PubMed ID: 29996726
[TBL] [Abstract][Full Text] [Related]
8. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
[TBL] [Abstract][Full Text] [Related]
9. Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib.
Elnair R; Galal A
BMC Cancer; 2018 Nov; 18(1):1097. PubMed ID: 30419862
[TBL] [Abstract][Full Text] [Related]
10. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.
Hochhaus A; Rosti G; Cross NC; Steegmann JL; le Coutre P; Ossenkoppele G; Petrov L; Masszi T; Hellmann A; Griskevicius L; Wiktor-Jedrzejczak W; Rea D; Coriu D; Brümmendorf TH; Porkka K; Saglio G; Gastl G; Müller MC; Schuld P; Di Matteo P; Pellegrino A; Dezzani L; Mahon FX; Baccarani M; Giles FJ
Leukemia; 2016 Jan; 30(1):57-64. PubMed ID: 26437782
[TBL] [Abstract][Full Text] [Related]
11. Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.
Crampe M; Shakkak F; Kelly J; Hodgson A; Langabeer SE
Leuk Lymphoma; 2017 Sep; 58(9):1-6. PubMed ID: 28121203
[No Abstract] [Full Text] [Related]
12. Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia.
Stein AM; Martinelli G; Hughes TP; Müller MC; Beppu L; Gottardi E; Branford S; Soverini S; Woodman RC; Hochhaus A; Kim DW; Saglio G; Radich JP
BMC Cancer; 2013 Apr; 13():173. PubMed ID: 23547655
[TBL] [Abstract][Full Text] [Related]
13. Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis.
Hochhaus A; Mahon FX; le Coutre P; Petrov L; Janssen JJWM; Cross NCP; Rea D; Castagnetti F; Hellmann A; Rosti G; Gattermann N; Coronel MLP; Gutierrez MAE; Garcia-Gutierrez V; Vincenzi B; Dezzani L; Giles FJ
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1225-1233. PubMed ID: 28224300
[TBL] [Abstract][Full Text] [Related]
14. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.
Ross DM; Masszi T; Gómez Casares MT; Hellmann A; Stentoft J; Conneally E; Garcia-Gutierrez V; Gattermann N; le Coutre PD; Martino B; Saussele S; Giles FJ; Radich JP; Saglio G; Deng W; Krunic N; Bédoucha V; Gopalakrishna P; Hochhaus A
J Cancer Res Clin Oncol; 2018 May; 144(5):945-954. PubMed ID: 29468438
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors.
Song HY; Noh H; Choi SY; Lee SE; Kim SH; Kee KM; Yoo HL; Lee MY; Kang KH; Suh JH; Yang SY; Jang EJ; Lee JI; Kim DW
Cancer Med; 2018 Oct; 7(10):5107-5117. PubMed ID: 30171671
[TBL] [Abstract][Full Text] [Related]
16. Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response.
O'Dwyer ME; Swords R; Nagler A; McMullin MF; le Coutre PD; Langabeer SE; Alvarez-Iglesias A; Fan H; Woodman RC; Giles FJ; Conneally E
Leuk Res; 2014 Mar; 38(3):310-5. PubMed ID: 24333114
[TBL] [Abstract][Full Text] [Related]
17. Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia: Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes.
Stuckey R; Casado LF; Colomer D; Gómez-Casares MT; Casas L; García-Gutierrez V; Sastre JL; Ramírez-Payer Á; Vall-Llovera F; Goñi MÁ; Xicoy B; Godoy AC; Núñez J; Mora I; Vallansot R; López-Lorenzo JL; Palomera L; Conesa V; Noya MS; Sánchez-Guijo F; Peña A; Bautista G; Steegmann JL
J Mol Diagn; 2020 Oct; 22(10):1217-1224. PubMed ID: 32688056
[TBL] [Abstract][Full Text] [Related]
18. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
Fava C; Rege-Cambrin G; Dogliotti I; Gottardi E; Berchialla P; Di Gioacchino B; Crasto F; Lorenzatti R; Volpengo A; Daraio F; Fantino C; Saglio G
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S96-S100. PubMed ID: 27131622
[TBL] [Abstract][Full Text] [Related]
19. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
Hughes TP; Saglio G; Kantarjian HM; Guilhot F; Niederwieser D; Rosti G; Nakaseko C; De Souza CA; Kalaycio ME; Meier S; Fan X; Menssen HD; Larson RA; Hochhaus A
Blood; 2014 Feb; 123(9):1353-60. PubMed ID: 24335106
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
